News

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
Opinion
FOX News on MSN17hOpinion
Dr. Oz details the new digital health ecosystem
Dr. Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, discusses the Trump administration’s efforts to eradicate Medicare and Medicaid fraud and build a digital health ...
President Donald Trump set a deadline of Sept. 19 for pharmaceutical companies to commit to complying with his demands of ...
Leadership at the Centers for Medicare and Medicaid Services is working with states to develop plans to use the $50 billion ...
Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...
The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...
More than a dozen Democratic attorneys general announced a lawsuit challenging recent moves by President Trump’s ...
Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...
The Trump administration is considering a shift in health care coverage, allowing Medicare and Medicaid to cover GLP-1 weight loss drugs.
The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...